Article
Radiological Evaluation of Newly Diagnosed Non-Brainstem Pediatric High-Grade Glioma in the HERBY Phase II Trial.
Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Apr 2020
Rodriguez Gutierrez Daniel, Jones Chris, Varlet Pascale, Mackay Alan, Warren Daniel, Warmuth-Metz Monika, Aliaga Esther Sánchez, Calmon Raphael, Hargrave Darren R, Cañete Adela, Massimino Maura, Azizi Amedeo A, Le Deley Marie-Cécile, Saran Frank, Rousseau Raphael F, Zahlmann Gudrun, Garcia Josep, Vassal Gilles, Grill Jacques, Morgan Paul S, Jaspan Tim
Abstract excerpt
PURPOSE: The HERBY trial evaluated the benefit of the addition of the antiangiogenic agent Bevacizumab (BEV) to radiotherapy/temozolomide (RT/TMZ) in pediatric patients with newly diagnosed non-brainstem high-grade glioma (HGG). The work presented here aims to correlate imaging characteristics and outcome measures with pathologic and molecular data. EXPERIMENTAL DESIGN: Radiological, pathologic, and molecular...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
